Sekisui Chemical Co Full-Year Report 2023

Group Overview

Net Sales: 1,256.5 billion yen (+1.1%), Operating Profit: 94.3 billion yen (+3.0%), Ordinary Profit: 105.9 billion yen (+1.6%), Profit Attributable to Owners of Parent: 77.9 billion yen (+12.5%) In fiscal 2023, net sales reached a record high as a result of a certain recovery in automobile-related demands as well as growth of sales of high value-added products and positive effects from foreign exchange rates, despite a prolonged slump in the domestic new housing market. 

Housing Company

Net Sales: 529.6 billion yen (-1.4%), Operating Profit: 27.7 billion yen (-15.5%) In fiscal 2023, net sales increased in the Housing Renovation business and Real Estate business, while in the Housing business, the number of houses ordered decreased year-on-year, and net sales slightly decreased year-on-year. Operating profit decreased due to factors such as rising prices for component parts, including the effects of foreign exchange rates. 

Urban Infrastructure and Environmental Products Company

Net Sales: 234.7 billion yen (+0.2%), Operating Profit: 22.1 billion yen (+4.4%) In fiscal 2023, despite the sluggish domestic housing and non-housing construction market as well as weak demand for chlorinated polyvinyl chloride (CPVC), securing profit by improving selling prices and the sales growth of prioritized products, such as polyethylene pipes for water supply, construction and factories, and fire protection materials, led to an increase in net sales. 

High Performance Plastics Company

Net Sales: 412.8 billion yen (+4.2%), Operating Profit: 50.9 billion yen (+27.0%) In fiscal 2023, both sales and profits increased due to a recovery in automobile-related demand, foreign exchange effects, and efforts to maintain or improve selling prices, despite the impact of sluggish demand for building materials and consumer goods in Europe, the U.S., and Japan. 

Medical Business

Net Sales: 92.6 billion yen (+3.3%), Operating Profit: 10.9 billion yen (-12.5%) In fiscal 2023, net sales increased year-on-year due to steadily capturing higher domestic demand for diagnostics primarily of infectious diseases, steady sales of new active pharmaceutical ingredients in the Pharmaceuticals and Fine Chemicals business, a focus on sales expansion of blood coagulation equipment and diagnostic reagents in China, as well as foreign exchange effects.